Member Info for 2phevs

https://www.prnewswire.com/nl/persberichten/johnson-matthey-launches-hycogen-an-enabling-technology-to-efficiently-convert-co2-and-green-hydrogen-into-sustainable-aviation-fuel-861587333.html
https://renewablesnow.com/news/johnson-matthey-launches-co2-utilisation-tech-to-produce-sustainable-fuels-768167/

just put daily limit sell on again for all shares @ 1.50 might be a little late putting it on tomorrow around 10am (work break time)

Just voted through Broadridge very simple and free through Fidelity all 7.4 million shares against all 5 resolutions

If anybody else has voted against please feel free to add to this thread
GLA

https://www.asktraders.com/analysis/ceres-power-understanding-the-basic-idea/

The companies customers pay on a 90/100 days basis suppliers are generally 30 days impacting cash flow (simple get an invoice finance facility any basic commercially aware person knows this let alone a CEO of a listed company)

I believe notlucky that a vote of 25%or more of NO will stop the resolutions being passed but if its around 20% the BOD could still not pass the resolutions because they feel they don't have enough support so vote NO because this BOD clearly doesn't give a toot cahoot about existing shareholders GL and be lucky

just took my rights castle 2mill@.1 but I'll be voting NO along with many more hopefully so probably won't get them anyway just tie up 2k for a few weeks

The more I think about this the more it stinks of current shareholder theft
It really smells disgustingly of just as the companies executives get a sniff of what potential glassware has they decide they want a huge slice of the cake via a back door 70% dilution
I'd love to know who the so called new "professional individual investors are"?
Vote NO

looks like you can't buy more than 500 quid a time at the ask getting tight

Yep Jon nice call

looks like someone building a position here GL whoever you are

DeepMatter is a big data and analysis company focused on enabling reproducibility and predictability in
chemistry. DeepMatter develops hardware and software to deliver applications resulting in new optimised
chemicals in areas that are commercially significant for the Group such as pharmaceutical research, fine
chemicals, scientific publications and teaching.
DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use
of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through
robotics. In the near term this involves the provision of an integrated software, hardware and artificial
intelligence enabled platform, DigitalGlassware™, to scientists across research and process
development sectors.
DigitalGlassware™, is a cloud-based software, proprietary hardware and machine learning-enabled
platform which eradicates reproducibility issues. Experiments are accurately and systematically recorded,
coded and entered into a shared data cloud, allowing scientists to collaborate effectively, sharing details
of their experiments from anywhere and in real-time.
DeepMatter operates in a growing market with CAGR of 4.7 per cent. from 2021 to 2028 - driven by
technology (digitalisation), compliance and economic necessity. Estimates suggest the market size of
this market is as follows:
• $486bn generated annually by the business of chemistry;
• $10bn invested in R&D by chemical companies in 2020; and
• $27bn in capital investments in the business of chemistry 2020.
The Group’s interim results published on 22 September 2021 highlighted the increase in commercial
traction with active users up 47 per cent and customers up to approximately 37. It stated that DeepMatter
is also working with five of the 20 largest pharmaceutical companies. Revenue increased to £0.6m and
the Group saw a strengthened sales pipeline and continued growth in users and trials. As at 30 June
2021, DeepMatter had cash of £1.8m.
As announced on 17 December 2021, DeepMatter is now in advanced discussions to provide its
DigitalGlassware® platform and data to Standigm Inc., a leading workflow artificial intelligence (AI) drug
discovery company, based in South Korea with an increasing international footprint. Based on current
discussions, the agreement is expected to generate mid six-figure revenue in the first 12 months. The
Group expects to now finalise the agreement in early 2022

Please add more if anyone would like to
As stated before great product and in a better commercial customer position than last 1.50 placing July 2020

ORDINARY RESOLUTION
4. Directors’ authority to allot shares
That, subject to and conditional upon the passing of Resolutions 1 and 2, the Directors be generally
and unconditionally authorised pursuant to section 551 of the Act to exercise all the powers of the
Company to allot and make offers to allot Relevant Securities (as defined below) up to an aggregate
nominal amount of £38,098.97.
Unless previously renewed, varied or revoked by the Company in a general meeting, this authority
shall expire 15 months after the date of the passing of this Resolution 4 or at the conclusion of the
next annual general meeting of the Company following the passing of this Resolution 4, whichever is
earlier, except that the Company may make an offer or agreement which would or might require equity
securities to be allotted after such expiry and the directors may allot equity securities in pursuance of
any such offer or agreement as if the power conferred hereby had not expired.
This Resolution 4 is in addition to the authority set out in Resolution 1 and all unexercised authorities
previously granted to the Directors to allot Relevant Securities.
For the purposes of this Resolution, a “Relevant Security” is:
(a) a share in the Company other than a share allotted pursuant to:
(i) an employee share scheme (as defined by section 1166 of the 2006 Act);
(ii) a right to subscribe for a share or shares in the Company where the grant of the right
itself constituted a Relevant Security under paragraph (b) below; or
(iii) a right to convert securities into a share or shares in the Company where the grant of the
right itself constituted a Relevant Security under paragraph (b) below.
(b) any right to subscribe for or to convert any security into a share or shares in the Company
other than a right to subscribe for or convert any security into a share or shares allotted
pursuant to an employee share scheme (as defined by section 1166 of the 2006 Act).
and references to the allotment of “Relevant Securities” in this Resolution 4 shall be construed
accordingly. (Oh and they want to convert £38,098 of granted employee share scheme into the subscription shocking!!)

just a bit of choice info from circular on dmtr website

If the Fundraising does not proceed and alternative immediate funding is not obtained in the limited
timeframe available, the Directors would need to consider whether it is appropriate for the Group
to cease trading and enter into a liquidation process. Accordingly, it is very important that
Shareholders vote in favour of the Fundraising Resolutions and that the Placing, Subscription and
Open Offer proceed. (I'm disgusted with this extortion language)

ORDINARY RESOLUTION
3. Restatement of the Option Pool
That, subject to and conditional upon the passing of Resolutions 1 and 2, the Directors be authorised
to restate the share option pool, in accordance with the rules of the Share Option Plan 2017, to
provide for the limitation thereunder (which disregards options which, if not exercised, have lapsed)
to be updated to not exceed 12% of the Enlarged Issued Share Capital. (they're trying to give themselves new share options at a very low price even though they've seriously underperformed since 2017 and they want 15 months to implement it incredulous!!)

If anyone wants to add to this list please do
I'm still voting NO

Just doubled up with 124k at 7.97 nice buying volume

Just put 1.50 limit sell order on my 7.4 million shares
GLA

Hi pablo I just think the resolutions won't be passed this paragraph along with a couple of other written clues in the latest rns.

The balance of any Open Offer Shares not subscribed for under the Excess Application Facility will not be available to subscribers under the Placing. There is no certainty that any funds will be raised under the Open Offer.

Firstly To state that "there is no certainty that any funds will be raised under the Open Offer" just screams that the main shareholders haven't been approached as the OO 1:3.7 £250,000.00@.010 matches exactly the existing shares in issue

Secondly the timing of the announcement when the biggest shareholder IP Group (25%ish) Glasgow University 5% and others would be on close down over Xmas smells very fishy.

Thirdly the holding off of the Korean mid six figure deal until this placing and OO is done wreaks of extortion.

And finally an in effect backdoor take over by NEW professional individual investors and existing ii (it mentions Springer gmbh and one of our Directors by name who also works for Springer) is exceptionally underhand

I might be completely wrong but as I've stated earlier my gut tells me different
GL pablo

There you go penny and Nathan 212811 buy and then sell trade just put a very limit sell on after you buy to stop them using your shares

Put my limit sell of 1.50 on all my 7.4 million shares so nobody can borrow them for any dirty games GLA

Not exactly exactly big at the moment but should be with the products looking forward 2 2022 GLA